Get the Stockscreener App
2.64
4.35%
0.11
Nrx Pharmaceuticals Inc stock is traded at $2.64, with a volume of 693.46K.
It is up +4.35% in the last 24 hours and down -11.71% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.53
Open:
$2.59
24h Volume:
693.46K
Relative Volume:
2.42
Market Cap:
$51.49M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.66
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-8.65%
1M Performance:
-11.71%
6M Performance:
+15.79%
1Y Performance:
+29.41%
1-Day Range:
$2.54
$2.69
1-Week Range:
$2.40
$2.86
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.64 | 53.83M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals Reports Progress in Drug Development Amid Financial Challenges - TipRanks
NRx Pharmaceuticals: A Biotech Powerhouse Navigating Ketamine and Bipolar Depression with Precision - AInvest
NRx Pharmaceuticals' Q2 2025: Unpacking Contradictions in Approval Pathways, Expansion Strategies, and Commercial Plans - AInvest
NRX Pharmaceuticals Sets Sights on $750M Ketamine Market with Expanded Fast Track for NRX-100 and Strengthened Balance Sheet - AInvest
Transcript : NRx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 20, 2025 - MarketScreener
Should you hold or exit NRx Pharmaceuticals Inc. Equity Warrant nowTrade Ideas & Capital Efficient Trading Techniques - Newser
How to use a screener to detect NRx Pharmaceuticals Inc. Equity Warrant breakouts2025 Historical Comparison & Real-Time Stock Movement Alerts - Newser
What to expect from NRx Pharmaceuticals Inc. Equity Warrant in the next 30 daysJuly 2025 Decliners & Smart Investment Allocation Insights - Newser
Is NRx Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Review & Comprehensive Market Scan Reports - Newser
Historical volatility pattern of NRx Pharmaceuticals Inc. Equity Warrant visualizedJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - Newser
Sector ETF performance correlation with NRx Pharmaceuticals Inc. Equity Warrant2025 Retail Activity & Daily Momentum Trading Reports - Newser
What recovery options are there for NRx Pharmaceuticals Inc. Equity WarrantPortfolio Return Report & Consistent Profit Trade Alerts - Newser
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs - MSN
Using data tools to time your NRx Pharmaceuticals Inc. exitRate Hike & Fast Exit Strategy with Risk Control - Newser
Visual analytics tools that track NRx Pharmaceuticals Inc. Equity Warrant performanceMarket Growth Report & Daily Volume Surge Signals - Newser
Why NRx Pharmaceuticals Inc. is moving todayQuarterly Trade Report & Safe Entry Momentum Tips - Newser
MACD Cross Could Confirm Trend in NRx Pharmaceuticals Inc.Gold Moves & Verified Technical Trade Signals - classian.co.kr
Milestone Pharmaceuticals shares rise 1.80% after-hours following positive corporate updates from NRx Pharmaceuticals. - AInvest
How hedge fund analytics apply to NRx Pharmaceuticals Inc. Equity Warrant stock2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can a trend reversal in NRx Pharmaceuticals Inc. lead to recoveryJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - Newser
Can technical indicators confirm NRx Pharmaceuticals Inc. Equity Warrant’s reversalJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
NRx Pharmaceuticals Reports Q2 2025 Results, Highlights Progress Across Lead Programs, Secures Strategic Investor Group Commitment - AInvest
NRx Pharmaceuticals, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - MarketScreener
NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to Expect - Yahoo Finance
NRX Pharmaceuticals Maintains 'Buy' Rating with $31 Price Target - AInvest
Nrx Pharmaceuticals Faces Uncertainty in Acquisitions Amid Financing Hurdles - AInvest
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - Amarillo Globe-News
NRx Pharmaceuticals Reports Q2 Loss, Cash Position Supports Operations Through 2026 - AInvest
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - ADVFN Brasil
Nrx Pharmaceuticals Faces Financing Hurdles in Strategic Acquisitions of Kadima and Dura Medical - TipRanks
NRx Pharmaceuticals: Pioneering a New Era in Suicidal Depression Therapeutics with Regulatory Momentum and Scalable Solutions - AInvest
NRX Pharmaceuticals Q2 2025 Earnings Miss: Market Impact and Strategic Insights - AInvest
Momentum Screeners Rank NRx Pharmaceuticals Inc. Equity Warrant in Top 5 Today2025 EndofYear Setup & Risk Controlled Daily Plans - beatles.ru
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products - ADVFN Brasil
NRx Pharmaceuticals Reports Q2 EPS at 98c, Attracts First Group of Fundamental Biotechnology Investors - AInvest
NRx Pharmaceuticals shares rise 1.45% after-hours after FDA grants expanded Fast Track Designation for NRX-100. - AInvest
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRX Pharmaceuticals Secures $6.5 Million Investment - TipRanks
NRx Pharmaceuticals reports Q2 FY25 financial results and provides corporate update. - AInvest
NRx Pharmaceuticals Reports Q2 2025 Financial Results - citybiz
NRx Pharmaceuticals reports Q2 EPS (98c) vs. (75c) last year - TipRanks
NRx Pharmaceuticals sees cash runway into 2026 - TipRanks
NRX Pharmaceuticals Reports Q2 2025 Financial Results: Focus on NMDA Platform for CNS Disorders - AInvest
Nrx Pharmaceuticals reports second quarter 2025 financial results - MarketScreener
What To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings - Yahoo Finance
NRx Drug Development: FDA Grants Expanded Fast Track Designation for NRX-100 - AInvest
NRx Pharmaceuticals Reports Q2 2025 Financial Results and Provides Corporate Update - AInvest
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second - GlobeNewswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
How NRx Pharmaceuticals Inc. stock performs during market volatilityForecast Cut & Expert Approved Trade Ideas - sundaytimes.kr
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):